CYBERNA
Cyberna is a biotechnology startup focused on revolutionizing cancer care through early detection using innovative in vitro diagnostic (IVD) tests. Their key product is a non-invasive blood test that detects epitranscriptomic signatures—chemical modifications of RNA—using mass spectrometry combined with artificial intelligence (machine learning). This approach enables early and accurate cancer diagnosis, particularly for colorectal cancer, by analyzing nucleoside biomarkers from a micro-blood sample. Founded in 2019 and officially established as a company in 2023, Cyberna has a multidisciplinary scientific and executive team with extensive biotech and diagnostic industry experience. The company has received recognition including a 2023 Innovation Trophy and national iLab program laureate status. Their business model includes offering their diagnostic platform as a scalable Software-as-a-Service (SaaS) solution, aiming to provide accessible, affordable, and fast cancer screening tools to improve patient outcomes globally.
CYBERNA
Cyberna is a biotechnology startup focused on revolutionizing cancer care through early detection using innovative in vitro diagnostic (IVD) tests. Their key product is a non-invasive blood test that detects epitranscriptomic signatures—chemical modifications of RNA—using mass spectrometry combined with artificial intelligence (machine learning). This approach enables early and accurate cancer diagnosis, particularly for colorectal cancer, by analyzing nucleoside biomarkers from a micro-blood sample. Founded in 2019 and officially established as a company in 2023, Cyberna has a multidisciplinary scientific and executive team with extensive biotech and diagnostic industry experience. The company has received recognition including a 2023 Innovation Trophy and national iLab program laureate status. Their business model includes offering their diagnostic platform as a scalable Software-as-a-Service (SaaS) solution, aiming to provide accessible, affordable, and fast cancer screening tools to improve patient outcomes globally.